Log in
NASDAQ:IART

Integra LifeSciences Competitors

$54.78
+0.25 (+0.46 %)
(As of 11/23/2020 12:00 AM ET)
Add
Compare
Today's Range
$54.00
Now: $54.78
$55.49
50-Day Range
$43.31
MA: $49.89
$56.13
52-Week Range
$34.21
Now: $54.78
$63.23
Volume303,556 shs
Average Volume565,855 shs
Market Capitalization$4.62 billion
P/E Ratio81.76
Dividend YieldN/A
Beta1.09

Competitors

Integra LifeSciences (NASDAQ:IART) Vs. ABT, MDT, SYK, ISRG, BDX, and EW

Should you be buying IART stock or one of its competitors? Companies in the sub-industry of "health care equipment" are considered alternatives and competitors to Integra LifeSciences, including Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton, Dickinson and (BDX), and Edwards Lifesciences (EW).

Abbott Laboratories (NYSE:ABT) and Integra LifeSciences (NASDAQ:IART) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and profitability.

Insider and Institutional Ownership

63.9% of Abbott Laboratories shares are held by institutional investors. Comparatively, 84.9% of Integra LifeSciences shares are held by institutional investors. 1.7% of Abbott Laboratories shares are held by insiders. Comparatively, 4.3% of Integra LifeSciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Abbott Laboratories and Integra LifeSciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Abbott Laboratories10.50%18.19%8.29%
Integra LifeSciences4.10%14.26%5.77%

Valuation & Earnings

This table compares Abbott Laboratories and Integra LifeSciences' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abbott Laboratories$31.90 billion6.07$3.69 billion$3.2433.73
Integra LifeSciences$1.52 billion3.04$50.20 million$2.7419.99

Abbott Laboratories has higher revenue and earnings than Integra LifeSciences. Integra LifeSciences is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings for Abbott Laboratories and Integra LifeSciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Abbott Laboratories141302.67
Integra LifeSciences16502.33

Abbott Laboratories currently has a consensus target price of $115.3750, suggesting a potential upside of 5.59%. Integra LifeSciences has a consensus target price of $55.9167, suggesting a potential upside of 2.07%. Given Abbott Laboratories' stronger consensus rating and higher probable upside, research analysts clearly believe Abbott Laboratories is more favorable than Integra LifeSciences.

Risk and Volatility

Abbott Laboratories has a beta of 0.9, meaning that its share price is 10% less volatile than the S&P 500. Comparatively, Integra LifeSciences has a beta of 1.09, meaning that its share price is 9% more volatile than the S&P 500.

Summary

Abbott Laboratories beats Integra LifeSciences on 10 of the 14 factors compared between the two stocks.

Integra LifeSciences (NASDAQ:IART) and Medtronic (NYSE:MDT) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings and analyst recommendations.

Analyst Ratings

This is a summary of recent recommendations and price targets for Integra LifeSciences and Medtronic, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Integra LifeSciences16502.33
Medtronic132012.84

Integra LifeSciences currently has a consensus price target of $55.9167, suggesting a potential upside of 2.07%. Medtronic has a consensus price target of $118.1538, suggesting a potential upside of 6.47%. Given Medtronic's stronger consensus rating and higher possible upside, analysts plainly believe Medtronic is more favorable than Integra LifeSciences.

Earnings & Valuation

This table compares Integra LifeSciences and Medtronic's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Integra LifeSciences$1.52 billion3.04$50.20 million$2.7419.99
Medtronic$28.91 billion5.16$4.79 billion$4.5924.18

Medtronic has higher revenue and earnings than Integra LifeSciences. Integra LifeSciences is trading at a lower price-to-earnings ratio than Medtronic, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Integra LifeSciences and Medtronic's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Integra LifeSciences4.10%14.26%5.77%
Medtronic15.80%10.47%5.80%

Volatility & Risk

Integra LifeSciences has a beta of 1.09, indicating that its share price is 9% more volatile than the S&P 500. Comparatively, Medtronic has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500.

Institutional and Insider Ownership

84.9% of Integra LifeSciences shares are held by institutional investors. Comparatively, 79.9% of Medtronic shares are held by institutional investors. 4.3% of Integra LifeSciences shares are held by company insiders. Comparatively, 0.5% of Medtronic shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Medtronic beats Integra LifeSciences on 10 of the 15 factors compared between the two stocks.

Stryker (NYSE:SYK) and Integra LifeSciences (NASDAQ:IART) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, profitability, dividends, valuation, analyst recommendations and earnings.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Stryker and Integra LifeSciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Stryker291512.56
Integra LifeSciences16502.33

Stryker presently has a consensus price target of $221.44, suggesting a potential downside of 4.97%. Integra LifeSciences has a consensus price target of $55.9167, suggesting a potential upside of 2.07%. Given Integra LifeSciences' higher possible upside, analysts plainly believe Integra LifeSciences is more favorable than Stryker.

Valuation & Earnings

This table compares Stryker and Integra LifeSciences' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Stryker$14.88 billion5.88$2.08 billion$8.2628.21
Integra LifeSciences$1.52 billion3.04$50.20 million$2.7419.99

Stryker has higher revenue and earnings than Integra LifeSciences. Integra LifeSciences is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Stryker and Integra LifeSciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Stryker11.38%20.53%8.89%
Integra LifeSciences4.10%14.26%5.77%

Volatility & Risk

Stryker has a beta of 0.78, indicating that its stock price is 22% less volatile than the S&P 500. Comparatively, Integra LifeSciences has a beta of 1.09, indicating that its stock price is 9% more volatile than the S&P 500.

Insider & Institutional Ownership

71.0% of Stryker shares are held by institutional investors. Comparatively, 84.9% of Integra LifeSciences shares are held by institutional investors. 6.8% of Stryker shares are held by company insiders. Comparatively, 4.3% of Integra LifeSciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Stryker beats Integra LifeSciences on 11 of the 15 factors compared between the two stocks.

Intuitive Surgical (NASDAQ:ISRG) and Integra LifeSciences (NASDAQ:IART) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, profitability, dividends, valuation, analyst recommendations and earnings.

Insider & Institutional Ownership

86.9% of Intuitive Surgical shares are held by institutional investors. Comparatively, 84.9% of Integra LifeSciences shares are held by institutional investors. 1.6% of Intuitive Surgical shares are held by company insiders. Comparatively, 4.3% of Integra LifeSciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Intuitive Surgical and Integra LifeSciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Intuitive Surgical371202.41
Integra LifeSciences16502.33

Intuitive Surgical presently has a consensus price target of $718.2778, suggesting a potential downside of 0.11%. Integra LifeSciences has a consensus price target of $55.9167, suggesting a potential upside of 2.07%. Given Integra LifeSciences' higher possible upside, analysts plainly believe Integra LifeSciences is more favorable than Intuitive Surgical.

Volatility & Risk

Intuitive Surgical has a beta of 0.97, indicating that its stock price is 3% less volatile than the S&P 500. Comparatively, Integra LifeSciences has a beta of 1.09, indicating that its stock price is 9% more volatile than the S&P 500.

Valuation & Earnings

This table compares Intuitive Surgical and Integra LifeSciences' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intuitive Surgical$4.48 billion18.87$1.38 billion$9.9572.27
Integra LifeSciences$1.52 billion3.04$50.20 million$2.7419.99

Intuitive Surgical has higher revenue and earnings than Integra LifeSciences. Integra LifeSciences is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Intuitive Surgical and Integra LifeSciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Intuitive Surgical24.45%12.08%10.44%
Integra LifeSciences4.10%14.26%5.77%

Summary

Intuitive Surgical beats Integra LifeSciences on 10 of the 14 factors compared between the two stocks.

Becton, Dickinson and (NYSE:BDX) and Integra LifeSciences (NASDAQ:IART) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings and risk.

Insider and Institutional Ownership

74.4% of Becton, Dickinson and shares are owned by institutional investors. Comparatively, 84.9% of Integra LifeSciences shares are owned by institutional investors. 0.1% of Becton, Dickinson and shares are owned by company insiders. Comparatively, 4.3% of Integra LifeSciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Becton, Dickinson and and Integra LifeSciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Becton, Dickinson and07712.60
Integra LifeSciences16502.33

Becton, Dickinson and presently has a consensus price target of $280.2857, suggesting a potential upside of 22.67%. Integra LifeSciences has a consensus price target of $55.9167, suggesting a potential upside of 2.07%. Given Becton, Dickinson and's stronger consensus rating and higher possible upside, equities analysts clearly believe Becton, Dickinson and is more favorable than Integra LifeSciences.

Risk and Volatility

Becton, Dickinson and has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500. Comparatively, Integra LifeSciences has a beta of 1.09, indicating that its share price is 9% more volatile than the S&P 500.

Valuation and Earnings

This table compares Becton, Dickinson and and Integra LifeSciences' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Becton, Dickinson and$17.12 billion3.87$874 million$10.2022.40
Integra LifeSciences$1.52 billion3.04$50.20 million$2.7419.99

Becton, Dickinson and has higher revenue and earnings than Integra LifeSciences. Integra LifeSciences is trading at a lower price-to-earnings ratio than Becton, Dickinson and, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Becton, Dickinson and and Integra LifeSciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Becton, Dickinson and5.11%13.30%5.60%
Integra LifeSciences4.10%14.26%5.77%

Summary

Becton, Dickinson and beats Integra LifeSciences on 10 of the 15 factors compared between the two stocks.

Edwards Lifesciences (NYSE:EW) and Integra LifeSciences (NASDAQ:IART) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings and risk.

Insider and Institutional Ownership

79.7% of Edwards Lifesciences shares are owned by institutional investors. Comparatively, 84.9% of Integra LifeSciences shares are owned by institutional investors. 1.5% of Edwards Lifesciences shares are owned by company insiders. Comparatively, 4.3% of Integra LifeSciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Edwards Lifesciences and Integra LifeSciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Edwards Lifesciences251302.55
Integra LifeSciences16502.33

Edwards Lifesciences presently has a consensus price target of $87.7222, suggesting a potential upside of 3.57%. Integra LifeSciences has a consensus price target of $55.9167, suggesting a potential upside of 2.07%. Given Edwards Lifesciences' stronger consensus rating and higher possible upside, equities analysts clearly believe Edwards Lifesciences is more favorable than Integra LifeSciences.

Risk and Volatility

Edwards Lifesciences has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500. Comparatively, Integra LifeSciences has a beta of 1.09, indicating that its share price is 9% more volatile than the S&P 500.

Valuation and Earnings

This table compares Edwards Lifesciences and Integra LifeSciences' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Edwards Lifesciences$4.35 billion12.14$1.05 billion$1.8645.54
Integra LifeSciences$1.52 billion3.04$50.20 million$2.7419.99

Edwards Lifesciences has higher revenue and earnings than Integra LifeSciences. Integra LifeSciences is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Edwards Lifesciences and Integra LifeSciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Edwards Lifesciences18.18%29.00%18.10%
Integra LifeSciences4.10%14.26%5.77%

Summary

Edwards Lifesciences beats Integra LifeSciences on 9 of the 14 factors compared between the two stocks.


Integra LifeSciences Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Abbott Laboratories logo
ABT
Abbott Laboratories
2.2$109.27+1.5%$193.67 billion$31.90 billion57.82
Medtronic logo
MDT
Medtronic
2.7$110.97+0.7%$149.17 billion$28.91 billion33.94
Stryker logo
SYK
Stryker
2.0$233.01+0.1%$87.56 billion$14.88 billion55.35
Intuitive Surgical logo
ISRG
Intuitive Surgical
1.7$719.05+1.6%$84.53 billion$4.48 billion81.90
Becton, Dickinson and logo
BDX
Becton, Dickinson and
2.0$228.48+1.5%$66.23 billion$17.12 billion83.69Increase in Short Interest
Edwards Lifesciences logo
EW
Edwards Lifesciences
1.8$84.70+0.2%$52.79 billion$4.35 billion67.76
Boston Scientific logo
BSX
Boston Scientific
2.4$33.33+1.1%$47.73 billion$10.74 billion12.77
IDEXX Laboratories logo
IDXX
IDEXX Laboratories
1.5$459.79+1.0%$39.22 billion$2.41 billion80.10
Baxter International logo
BAX
Baxter International
2.3$75.77+1.6%$38.70 billion$11.36 billion43.05Increase in Short Interest
DexCom logo
DXCM
DexCom
2.1$321.09+1.6%$30.83 billion$1.48 billion132.68
ResMed logo
RMD
ResMed
1.7$209.57+0.7%$30.37 billion$2.96 billion49.08
Insulet logo
PODD
Insulet
1.3$265.89+0.2%$17.53 billion$738.20 million949.64
Hologic logo
HOLX
Hologic
1.9$68.07+1.4%$17.49 billion$3.37 billion16.21Analyst Downgrade
Teleflex logo
TFX
Teleflex
1.8$373.14+0.7%$17.38 billion$2.60 billion36.73
STERIS logo
STE
STERIS
1.9$189.09+3.5%$16.13 billion$3.03 billion39.31
Varian Medical Systems logo
VAR
Varian Medical Systems
1.4$173.50+0.0%$15.78 billion$3.23 billion56.51
Masimo logo
MASI
Masimo
1.6$245.50+1.0%$13.52 billion$937.84 million63.77
Abiomed logo
ABMD
Abiomed
1.5$266.43+0.7%$12.04 billion$840.88 million58.56
Hill-Rom logo
HRC
Hill-Rom
1.9$97.55+0.1%$6.52 billion$2.91 billion31.47Unusual Options Activity
Globus Medical logo
GMED
Globus Medical
1.5$58.47+1.1%$5.77 billion$785.37 million63.55
Wright Medical Group logo
WMGI
Wright Medical Group
1.1$29.98+0.0%$3.90 billion$920.90 million-28.28
CONMED logo
CNMD
CONMED
1.5$103.32+2.0%$2.96 billion$955.10 million108.76Dividend Announcement
Insider Selling
NuVasive logo
NUVA
NuVasive
1.8$47.18+2.3%$2.42 billion$1.17 billion-214.45
Integer logo
ITGR
Integer
2.2$71.37+2.1%$2.35 billion$1.26 billion32.44
AtriCure logo
ATRC
AtriCure
1.5$43.24+1.8%$1.95 billion$230.81 million-37.60
Cardiovascular Systems logo
CSII
Cardiovascular Systems
1.7$34.90+1.2%$1.40 billion$236.54 million-52.88Analyst Downgrade
Alphatec logo
ATEC
Alphatec
1.2$10.55+2.4%$827.38 million$113.43 million-9.59
CryoLife logo
CRY
CryoLife
2.1$20.87+4.0%$810.95 million$276.22 million-54.92
Orthofix Medical logo
OFIX
Orthofix Medical
1.4$37.14+2.7%$718.07 million$459.95 million30.95
Surmodics logo
SRDX
Surmodics
1.5$38.12+2.4%$518.66 million$100.08 million68.07
AngioDynamics logo
ANGO
AngioDynamics
1.5$12.52+0.6%$475.17 million$264.16 million-2.83
Accuray logo
ARAY
Accuray
2.0$4.40+11.1%$401.61 million$382.93 million31.43High Trading Volume
Unusual Options Activity
Invacare logo
IVC
Invacare
1.4$8.98+1.1%$309.07 million$927.96 million-7.30
Rockwell Medical logo
RMTI
Rockwell Medical
1.3$0.94+1.1%$88.32 million$61.30 million-2.10
This page was last updated on 11/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.